At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 121 enrolled
Drug / intervention
Cetuximab +3 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Randomized, Open-Label Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and Carboplatin in Patients With Stage IIIB/IV Non-Small Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating Cetuximab, Bevacizumab, and 2 other interventions for Non-Small Cell Lung Cancer. Completed, enrolled 121 participants across 43 sites.
Detailed Summary
The primary objective of this study will be to determine the progression free survival of patients with stage IIIb/IV non-small cell lung cancer (NSCLC) treated with dual agent monoclonal antibody therapy consisting of cetuximab and bevacizumab in combination with two different regimens of paclitaxel and carboplatin chemotherapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Small Cell Lung Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 2006
Enrollment StartDec 2006
Primary CompletionMay 2010
Study CompletionDec 2010
TodayJul 2026
First PostedJun 22, 2006
Enrollment StartDec 1, 2006
Primary CompletionMay 1, 2010
Study CompletionDec 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 20.0 years ago
Interventions
Cetuximabbiological
Administered intravenously
Bevacizumabbiological
Administered intravenously
Paclitaxeldrug
Administered intravenously
Carboplatindrug
Administered intravenously